Pub. Date : 2013 Mar
PMID : 22777148
7 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Rate of onset of inhibition of gut-wall and hepatic CYP3A by clarithromycin. | Clarithromycin | cytochrome P450 family 3 subfamily A member 4 | Homo sapiens |
| 2 | AIMS: To determine the extent and time-course of hepatic and intestinal cytochrome P450 3A (CYP3A) inactivation due to the mechanism-based inhibitor clarithromycin. | Clarithromycin | cytochrome P450 family 3 subfamily A member 4 | Homo sapiens |
| 3 | AIMS: To determine the extent and time-course of hepatic and intestinal cytochrome P450 3A (CYP3A) inactivation due to the mechanism-based inhibitor clarithromycin. | Clarithromycin | cytochrome P450 family 3 subfamily A member 4 | Homo sapiens |
| 4 | RESULTS: Intestinal CYP3A activity decreased by 64 % (p = 0.0029) following the first dose of clarithromycin, but hepatic CYP3A activity did not significantly decrease. | Clarithromycin | cytochrome P450 family 3 subfamily A member 4 | Homo sapiens |
| 5 | Repeated dosing of clarithromycin caused a significant decrease in hepatic CYP3A activity (p = 0.005), while intestinal activity showed little further decline. | Clarithromycin | cytochrome P450 family 3 subfamily A member 4 | Homo sapiens |
| 6 | CONCLUSIONS: Following the administration of clarithromycin, the onset of hepatic CYP3A inactivation is delayed compared to that of intestinal CYP3A. | Clarithromycin | cytochrome P450 family 3 subfamily A member 4 | Homo sapiens |
| 7 | The time-course of drug-drug interactions due to clarithromycin will vary with the relative contribution of intestinal and hepatic CYP3A to the clearance and bioavailability of a victim substrate. | Clarithromycin | cytochrome P450 family 3 subfamily A member 4 | Homo sapiens |